Retatrutide is a 39-amino-acid synthetic peptide and a triple agonist of the GLP-1, GIP, and glucagon receptors, originally developed by Eli Lilly as LY3437943. It has been studied extensively in metabolic research for its relationship to adiposity, glucose homeostasis, and energy expenditure across both preclinical and phase-trial settings. Its triple-receptor profile places it in a distinct category from earlier dual-agonist peptide designs and gives the compound a broader signaling architecture within incretin research. Lyophilized powder, 3mL vial. Sold at 10mg, 20mg, 30mg, and 40mg per vial. For research use only.
